Sun Pharma's Profit Declines 20% Despite Strong Indian Market Growth
Sun Pharmaceutical Industries reported a 20% decline in consolidated net profit for Q1 2025, with profits falling to Rs 2,279 crore from Rs 2,836 crore the previous year. Despite this, adjusted net profit rose 6% to Rs 2,996 crore. Chairman Dilip Shanghvi highlighted strong market growth in India and the launch of LEQSELVI in the US.

- Country:
- India
Sun Pharmaceutical Industries announced a 20% decline in its consolidated net profit for the first quarter of 2025, reporting Rs 2,279 crore compared to Rs 2,836 crore for the same period last year.
Adjusted net profit, which excludes exceptional items, showed a 6% year-on-year increase to Rs 2,996 crore. Total income also saw an uptrend, rising to Rs 14,316 crore from Rs 13,185 crore the previous year.
According to Chairman and Managing Director Dilip Shanghvi, the Mumbai-based drug major has shown steady growth across its markets, bolstered by strong performance in India and the US launch of LEQSELVI, a new treatment for severe alopecia areata. Despite this optimistic scenario, shares of the company fell by 2.04% on the BSE.
(With inputs from agencies.)
ALSO READ
Crackdown on Fake Pharmaceuticals: Factory Owner Arrested in Uttarakhand
Alembic Pharmaceuticals Secures USFDA Nod for Carbamazepine Tablets
Torrent Pharmaceuticals: Riding the Wave of Revenue Growth
India-UK Trade Deal: A New Era for Pharmaceuticals
Massive Seizure of Unlicensed Pharmaceuticals in Delhi